Oral Abstract Data Presentation at ASCO, Chicago (June 3 – 7, 2011) | |
Abstract #6508 | |
Title: Activity and tolerability of the Bruton's tyrosine kinase (Btk) inhibitor PCI-32765 in patients with chronic lymphocytic leukemia/small cell lymphocytic lymphoma (CLL/SLL): Interim results of a Phase Ib/II study. J.C. Byrd et al. | |
Date/Time: Monday, June 6, 2011; Oral Abstract Session: 9:30 AM – 12:30 PM | |
Session Title: Leukemia, Myelodysplasia and Transplantation | |
Location: Arie Crown Theater | |
Oral Abstract Data Presentations at ICML, Lugano, Switzerland (June 15-18, 2011)
| |
Abstract # 122 | |
Title: The Btk Inhibitor PCI-32765 is Highly Active and Tolerable in Patients with Poor-Risk CLL: Interim Results from a Phase Ib/II Study. S. O'Brien et al. | |
Date/Time: Friday, June 17, 2011; 9:45 AM | |
Session 10: Chronic Lymphocytic Leukemia (CLL) | |
Location: Room A, B, C and Marquee Parco Ciani) | |
Abstract # 153 | |
Title: The Btk inhibitor PCI-32765 is highly active and well tolerated in patients (pts) with relapsed/refractory B-cell malignancies: Final results from a Phase Ia study. R.H. Advani et al. | |
Date/Time: Saturday, June 18, 2011; 9:30 AM | |
Session 14: Signaling Pathways in Lymphoma | |
Location: Room A | |
